July 20, 2019
Marker today announced interim data from an ongoing investigator-sponsored clinical trial led by Baylor College of Medicine, evaluating the Company’s MultiTAA T cell therapy in patients with pancreatic adenocarcinoma. The data were reviewed today in an oral presentation during a plenary session, as well as a poster presentation, at the American Association for Cancer Research’s (AACR) Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy conference held in San Francisco, California from July 19-22, 2019.
February 25, 2019
Marker Therapeutics announces updated data from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies.
February 20, 2019
President and CEO, Peter L. Hoang, and Chief Development Officer, Dr. Juan Vera, will be presenting at the CAR-TCR Summit Europe.
January 3, 2019
The Company has announced a year-end update in five clinical trials using the Company’s therapeutic products, LAPP and MAPP multi-antigen targeted T cell (MultiTAA) therapies and TPIV200, its Folate Receptor Alpha (FRα) peptide cancer vaccine product candidate.